A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MVA / modified virus Ankara

[Related PubMed/MEDLINE]
Total Number of Papers: 15
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MVA  (>> Co-occurring Abbreviation)
Long Form:   modified virus Ankara
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2016 Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis. AE
2012 Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines. ---
2012 Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. CS, PPV-VLPs, VACV, WR
2010 Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation. IKKbeta, NF-kappaB, VACV
2009 A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. BCG
2007 Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. CSP
2007 Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells. DC, WR
2006 Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. HIV-1
2006 The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. DCs, ELISPOT, TAA, WR
10  2005 Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help. ---
11  2005 Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. ---
12  2005 Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. rMVA
13  1999 Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. CTL, HIV, SIV
14  1998 Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. CTL, HIV, IFN
15  1998 Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. CEFs, IFN